Compare AFBI & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFBI | EQ |
|---|---|---|
| Founded | 1928 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.6M | 129.0M |
| IPO Year | 2020 | 2018 |
| Metric | AFBI | EQ |
|---|---|---|
| Price | $22.49 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 12.0K | ★ 252.6K |
| Earning Date | 04-24-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.42 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $62.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.86 | $0.29 |
| 52 Week High | $22.50 | $2.70 |
| Indicator | AFBI | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 70.58 | 53.44 |
| Support Level | $22.41 | $1.60 |
| Resistance Level | $22.50 | $2.61 |
| Average True Range (ATR) | 0.03 | 0.24 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 75.00 | 52.54 |
Affinity Bancshares Inc is a bank holding company. The bank provides a range of financial services, including checking and savings accounts, certificates of deposit, mortgage, commercial and consumer loans, and money transfer services, operating across parts of Georgia and offering specialized lending such as dental practice and indirect automobile loans across the Southeastern United States. Its business mainly involves accepting public deposits and investing them in real estate and commercial loans, as well as mortgage-backed securities. The company also gathers deposits nationwide through its virtual bank, FitnessBank, and uses additional funding sources such as Federal Home Loan Bank borrowings.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.